CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
5.83
-0.17 (-2.83%)
Aug 21, 2026, 4:00 PM EDT - Market closed

CNS Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
6.816.215.614.775.974.68
Research & Development
10.119.779.2914.19.39.81
Operating Expenses
16.9115.9914.918.8715.2714.49
Operating Income
-16.91-15.99-14.9-18.87-15.27-14.49
Interest Expense
-0.02-0.02-0.02-0.01-0.01-0.01
Interest & Investment Income
0.230.150.060.03--
Other Non Operating Income (Expenses)
-0-0----
EBT Excluding Unusual Items
-16.7-15.85-14.86-18.85-15.27-14.5
Pretax Income
-16.7-15.85-14.86-18.85-15.27-14.5
Net Income
-16.7-15.85-14.86-18.85-15.27-14.5
Net Income to Common
-16.7-15.85-14.86-18.85-15.27-14.5
Net Income Growth
------
Shares Outstanding (Basic)
200---
Shares Outstanding (Diluted)
200---
Shares Change
1105.07%1293.23%----
EPS (Basic)
-7.66-35.75-466.89---
EPS (Diluted)
-7.66-35.75-466.89---
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-13.44-13.83-17.12-14.14-10.56-13.54
Free Cash Flow Per Share
-6.16-31.19-537.90---
EBITDA
-16.9-15.98-14.9-18.86-15.26-14.47
D&A For EBITDA
0.010000.010.01
EBIT
-16.91-15.99-14.9-18.87-15.27-14.49
SEC Filings: 10-K · 10-Q